Treatment update in small-cell lung cancer: From limited to extensive disease

Current Treatment Options in Oncology

Volumn 13, Issue 4, 2012, Pages 505-515

  Spigel, David R ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Chemoradiation; Extensive stage; Limited stage; Small cell lung cancer

Indexed keywords

AMRUBICIN; ANTHRACYCLINE DERIVATIVE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BETA CAROTENE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6 INDUCING AGENT; CYTOCHROME P450 2B6 INHIBITOR; CYTOCHROME P450 3A4 INDUCING AGENT; CYTOCHROME P450 3A4 INHIBITOR; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; ENZYME INDUCING AGENT; ENZYME INHIBITOR; ETOPOSIDE; GEMCITABINE; IMATINIB; IRINOTECAN; LIVER ENZYME; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ABDOMINAL CRAMP; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN RADIATION; CANCER GROWTH; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONSTIPATION; COUGHING; CREATININE CLEARANCE; DEHYDRATION; DIAPHORESIS; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FLATULENCE; FLUSHING; GENETIC MANIPULATION; GLUCURONIDATION; HEART EJECTION FRACTION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INSOMNIA; LACRIMATION; LIVER METABOLISM; LUNG SMALL CELL CANCER; MIOSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PAIN; PERIPHERAL NEUROPATHY; RHINITIS; SALIVATION; SIDE EFFECT; SMOKING; SMOKING CESSATION; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VASODILATATION; WEAKNESS; WEIGHT REDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; SMALL CELL LUNG CARCINOMA; TOPOTECAN;

EID: 84870853881     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0212-6     Document Type: Article

References (33)

1. American Cancer Society. Cancer facts and figures 2012; 2012.
2. Stupp R, Monnerat C, Turrisi 3rd AT, et al. Small cell lung cancer: state of the art and future perspectives. Lung Cancer. 2004;45:105-17.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539-44.
4. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340(22):1733.
5. Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer. 2008;113 (1):150.
6. Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. JNCI J Natl Cancer Inst. 1998;90(18):1335-45. doi:10.1093/jnci/90.18.1335.
7. Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? a meta-analysis of randomized trials of a cisplatincontaining regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83(1):8.
8. Rossi A, Massimo Di Maio, Chiodini P. Carboplatinor cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS metaanalysis of individual patient data. JCO May 10, 2012:1692-1698.
9. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M, Suemasu KSO. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83(12):855.
10. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10(2):282.
11. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85.
12. Hanna N, Bunn Jr PA, Langer C, Einhorn L, Guthrie Jr T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. ASOJ Clin Oncol. 2006;24(13):2038.
13. Lara Jr PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara D. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. Clin Oncol. 2009;27(15):2530.
14. Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, Cisar L, Soria JC, Domine M, Thomas M. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810.
15. Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26(26):4261.
16. von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, Richardson G, Steppert C, Rivière A, Camlett I, Lane S, Ross G. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19(6):1743.
17. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086.
18. Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K. Phase II Trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006;24(34):5448.
19. Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010;28:2598-603.
20. Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF, Oliver JW. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinumbased chemotherapy. JCO. 2011;29(3):287-93.
21. Jotte R, Von Pawel J, Spigel DR, Socinski MA, O'Brien M, Paschold EH, Mezger J, Steins M, Bosquée L, Bubis JA, Nackaerts K, Trigo Perez JM, Clingan PR, Schuette W, Lorigan P, Reck M, Domine M, Shepherd FA, McNally R, Renschler MF. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). J Clin Oncol (Meeting Abstracts). 2011;29(15):suppl 7000.
22. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009;27(35):6006.
23. Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011;29(33):4436.
24. Spigel DR, Greco FA, Zubkus JD, Murphy PB, Saez RA, Farley C, Yardley DA, Burris 3rd HA, Hainsworth JD. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol. 2009;4(12):1555-60.
25. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29(16):2215.
26. Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol. 2010;5(2):215.
27. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B. A meta-analysis of thoracic radiotherapy for smallcell lung cancer. N Engl J Med. 1992;327(23):1618.
28. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? a meta-analysis. J Clin Oncol. 1992;10(6):890.
29. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, Gerstner JB, Maksymiuk A, Levitt R, Mailliard JA, Tazelaar HD, Hillman S, Jett Jr. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17(9):2681.
30. Turrisi 3rd AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265.
31. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, Payne D, Kostashuk EC, Evans WK, Dixon P. J Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage smallcell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11 (2):336.
32. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev. 2005.
33. Park K, Sun J-M, Kim S-W, Ahn M-j, Ahn JS, Lee DH, Suh C, Ahn YC, Pyo H, Choi EK, Song SY, Lee S-H, Lee JS. Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limiteddisease small cell lung cancer. J Clin Oncol (Meeting Abstracts). 2012;30(15):suppl 7004.